Autoimmune Gastritis Classification
Autoimmune gastritis is not classified into distinct clinical "types" but rather represents a single disease entity characterized by corpus-predominant atrophic gastritis with varying stages of progression and clinical manifestations. 1
Understanding Autoimmune Gastritis as a Unified Entity
Autoimmune gastritis (AIG) is fundamentally one disease process—an immune-mediated destruction of gastric parietal cells in the corpus/fundus region. Unlike other conditions that have multiple subtypes, AIG follows a predictable pattern of progression rather than branching into different types 2, 3.
Key Distinguishing Features from Other Gastritis Forms
The critical distinction is etiologic, not typologic:
- Autoimmune gastritis: Corpus-predominant atrophy due to autoimmunity (0.5-2% prevalence) 1
- H. pylori-associated atrophic gastritis: Antrum-predominant initially, can become multifocal (dominant etiology globally) 1
Clinical Spectrum and Stages of Progression
Rather than types, AIG presents along a continuum of severity:
Early/Asymptomatic Stage
- Corpus atrophy without clinical manifestations
- May have positive antiparietal cell antibodies
- No nutritional deficiencies yet 3, 4
Intermediate Stage
- Iron deficiency anemia (due to achlorhydria impairing iron absorption)
- Vitamin B12 deficiency developing
- Corpus-predominant atrophy on histology 1, 2
Advanced Stage (Pernicious Anemia)
- Pernicious anemia represents the late-stage manifestation of AIG, not a separate type
- Characterized by megaloblastic anemia from severe B12 deficiency
- Indicates years of corpus-predominant atrophy 1
- Prevalence: 0.15-1% (much rarer than AIG itself) 1
Neoplastic Complications
- Type 1 gastric neuroendocrine tumors (2.8% incidence per person-year) 3
- Gastric adenocarcinoma risk (0.5% incidence per person-year) 3
Recently Recognized Variants (Not True "Types")
Recent literature has identified two diagnostic scenarios that warrant mention:
"Potential AIG"
- Early serological evidence without established histological atrophy
- Represents pre-atrophic phase 2
"Seronegative AIG"
- Histological features of AIG without detectable autoantibodies
- Previously overlooked diagnostic entity 2
These are diagnostic considerations rather than distinct disease types, reflecting the evolving understanding of AIG's natural history.
Clinical Manifestation Patterns
While not "types," AIG presents with different clinical phenotypes based on which deficiency predominates 4, 5:
- Hematological: Iron deficiency anemia, pernicious anemia
- Neurological: B12 deficiency-related neuropathy, psychiatric symptoms
- Gastrointestinal: Dyspepsia, reflux symptoms (often minimal)
- Gynecological-obstetric: Less common presentations
Critical Diagnostic Approach
The diagnosis requires corpus-predominant atrophic gastritis on histology 1. When suspected:
- Obtain topographical biopsies from body and antrum in separate jars 1
- Check antiparietal cell antibodies and anti-intrinsic factor antibodies 1
- Assess for vitamin B12 and iron deficiencies 1
- Screen for H. pylori (must be excluded as alternative etiology) 1
- Evaluate for concomitant autoimmune disorders, particularly thyroid disease (present in up to one-third of patients) 1
Common Pitfall
The major pitfall is conceptualizing AIG as having multiple "types" when it is actually a single disease with variable clinical presentations and stages of progression. The distinction that matters clinically is between autoimmune and H. pylori-associated atrophic gastritis, as they have different anatomic distributions, risk profiles, and management implications 1.